{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T02:23:55Z","timestamp":1771467835485,"version":"3.50.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.ejpb.2023.02.007","type":"journal-article","created":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T02:21:39Z","timestamp":1677032499000},"page":"28-43","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Tacrolimus and paclitaxel co-loaded O\/O ointment without surfactant: Synergistic combinations for the treatment of psoriasis"],"prefix":"10.1016","volume":"185","author":[{"given":"Wenxue","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenxiu","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meijuan","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sichen","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ru","family":"Mi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2089-1982","authenticated-orcid":false,"given":"Hongyu","family":"Piao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2023.02.007_b0005","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.clindermatol.2007.08.007","article-title":"Psoriasis: epidemiology","volume":"25","author":"Gudjonsson","year":"2007","journal-title":"Clin. Dermatol."},{"key":"10.1016\/j.ejpb.2023.02.007_b0010","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/jid.2012.339","article-title":"Identification, P. Management of, t. Associated ComorbidiTy project, Global epidemiology of psoriasis: a systematic review of incidence and prevalence","volume":"133","author":"Parisi","year":"2013","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.ejpb.2023.02.007_b0015","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.amjmed.2018.05.013","article-title":"Psoriasis and psoriatic spectrum disease: a primer for the primary care physician","volume":"131","author":"Bilal","year":"2018","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ejpb.2023.02.007_b0020","first-page":"7","article-title":"Current knowledge on psoriasis and autoimmune diseases","volume":"6","author":"Ayala-Fontanez","year":"2016","journal-title":"Psoriasis (Auckl)"},{"key":"10.1016\/j.ejpb.2023.02.007_b0025","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20061475","article-title":"Psoriasis pathogenesis and treatment","volume":"20","author":"Rendon","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejpb.2023.02.007_b0030","unstructured":"J.M. Gelfand, J. Wan, K. Callis Duffin, G. G. Krueger, R. E. Kalb, J. D. Weisman, B. R. Sperber, PhD; M. B. Stierstorfer, B. A. Brod, S. M. Schleicher, B. F. Bebo Jr, A. B. Troxel, D. B. Shin, J.M. Steinemann, J. Goldfarb, H.Yeung, A.S.V. Voorhees, Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting, Archives of dermatology, 148 2012 487-494."},{"key":"10.1016\/j.ejpb.2023.02.007_b0035","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1468-3083.2009.03358.x","article-title":"C. International Psoriasis, Topical corticosteroids in psoriasis: strategies for improving safety","volume":"24","author":"Horn","year":"2010","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.ejpb.2023.02.007_b0040","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1046\/j.1468-3083.2002.00380.x","article-title":"Tacrolimus: a review of its use for the management of dermatoses","volume":"16","author":"Gupta","year":"2002","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.ejpb.2023.02.007_b0045","unstructured":"H. G, What's new in topical treatments for psoriasis, Cutis102 2018 65-66."},{"key":"10.1016\/j.ejpb.2023.02.007_b0050","first-page":"153","article-title":"Tacrolimus for the management of psoriasis: clinical utility and place in therapy","volume":"6","author":"Malecic","year":"2016","journal-title":"Psoriasis (Auckl)"},{"key":"10.1016\/j.ejpb.2023.02.007_b0055","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s102270000022","article-title":"Tacrolimus in dermatology","volume":"5","author":"De Tran","year":"2001","journal-title":"J. Cutan. Med. Surg."},{"key":"10.1016\/j.ejpb.2023.02.007_b0060","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/1346-8138.14501","article-title":"Tacrolimus ointment for the treatment of adult and pediatric atopic dermatitis: review on safety and benefits","volume":"45","author":"Ohtsuki","year":"2018","journal-title":"J. Dermatol."},{"key":"10.1016\/j.ejpb.2023.02.007_b0065","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0091-6749(98)70281-7","article-title":"A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children","volume":"102","author":"Boguniewicz","year":"1998","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ejpb.2023.02.007_b0070","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/jnci\/82.15.1247","article-title":"Taxol: a novel investigational antimicrotubule agent","volume":"82","author":"Rowinsky","year":"1990","journal-title":"J. Natl Cancer Inst."},{"key":"10.1016\/j.ejpb.2023.02.007_b0075","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jaad.2003.09.018","article-title":"Micellar paclitaxel improves severe psoriasis in a prospective phase II pilot study","volume":"50","author":"Ehrlich","year":"2004","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.ejpb.2023.02.007_b0080","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jconrel.2012.06.021","article-title":"Development of paclitaxel-TyroSpheres for topical skin treatment","volume":"163","author":"Kilfoyle","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2023.02.007_b0085","unstructured":"Laura A. Martello, Hayley M. McDaid, Donna Lee Regl, Chia-Ping H. Yang, Dongfang Meng, Thomas R. R. Pettus, Michael D. Kaufman, Hirokazu Arimoto, Samuel J. Danishefsky, Amos B. Smith III, S.B. Horwitz2, Taxol and discodermolide represent a synergistic drug combination in human carcinoma cell lines, Clinical Cancer Research 6 2000 1978-1987."},{"key":"10.1016\/j.ejpb.2023.02.007_b0090","first-page":"1","article-title":"Safety considerations with combination therapies for psoriasis","author":"Nakamura","year":"2020","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.ejpb.2023.02.007_b0095","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.1021\/acsami.5b09340","article-title":"Paclitaxel and tacrolimus coencapsulated polymeric micelles that enhance the therapeutic effect of drug-resistant ovarian cancer","volume":"8","author":"Wang","year":"2016","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.ejpb.2023.02.007_b0100","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3109\/09546634.2015.1052036","article-title":"Topical combination therapy with vitamin D3 and corticosteroid ointment for palmoplantar pustulosis: a prospective, randomized, left-right comparison study","volume":"27","author":"Muro","year":"2015","journal-title":"J. Dermatolog. Treat."},{"key":"10.1016\/j.ejpb.2023.02.007_b0105","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1208\/s12249-019-1413-0","article-title":"A Novel Surfactant-Free O\/O paclitaxel ointment for the topical treatment of psoriasis","volume":"20","author":"Yin","year":"2019","journal-title":"AAPS PharmSciTech."},{"key":"10.1016\/j.ejpb.2023.02.007_b0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1208\/s12249-019-1413-0","article-title":"A novel surfactant-free O\/O paclitaxel ointment for the topical treatment of psoriasis","volume":"20","author":"Yin","year":"2019","journal-title":"AAPS PharmSciTech."},{"key":"10.1016\/j.ejpb.2023.02.007_b0115","doi-asserted-by":"crossref","unstructured":"SHIGEKI TAMURA, ATSUO OHIKE, RINTA IBUKI, GORDON L. AMIDON, S. YAMASHITA, Tacrolimus is a class II low-solubility high-permeability drug: the effect of P-glycoprotein efflux on regional permeability of tacrolimus in rats, 91 3 719-729., Journal of pharmaceutical sciences, 91 2002 719-729.","DOI":"10.1002\/jps.10041"},{"key":"10.1016\/j.ejpb.2023.02.007_b0120","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jconrel.2017.01.014","article-title":"BCS class IV drugs: highly notorious candidates for formulation development","volume":"248","author":"Ghadi","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2023.02.007_b0125","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.3892\/ijmm.2017.2930","article-title":"Paeonol ameliorates imiquimod-induced psoriasis-like skin lesions in BALB\/c mice by inhibiting the maturation and activation of dendritic cells","volume":"39","author":"Meng","year":"2017","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.ejpb.2023.02.007_b0130","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.4049\/jimmunol.0802999","article-title":"Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23\/IL-17 axis","volume":"182","author":"van der Fits","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejpb.2023.02.007_b0135","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1080\/01926230600867743","article-title":"Normal structure, function, and histology of the spleen","volume":"34","author":"Cesta","year":"2006","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.ejpb.2023.02.007_b0140","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1365-2133.1992.tb07805.x","article-title":"Is epidermal cell proliferation in psoriatic skin grafts on nude mice driven by T-cell derived cytokines?","volume":"126","author":"Baker","year":"1992","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.ejpb.2023.02.007_b0145","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13058-015-0538-7","article-title":"RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy","volume":"17","author":"Azim","year":"2015","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ejpb.2023.02.007_b0150","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(96)00423-1","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"23","author":"Lipinski","year":"1997","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2023.02.007_b0155","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0002-9343(97)00178-2","article-title":"Beutner, Stephen Tyring, Human papillomavirus and human disease","volume":"102","author":"Karl","year":"1997","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ejpb.2023.02.007_b0160","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cytogfr.2014.10.009","article-title":"An inflammatory triangle in psoriasis: TNF, type I IFNs and IL-17","volume":"26","author":"Grine","year":"2015","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.ejpb.2023.02.007_b0165","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nri3477","article-title":"The role of dendritic cells in autoimmunity","volume":"13","author":"Ganguly","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejpb.2023.02.007_b0170","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jconrel.2016.10.004","article-title":"Tacrolimus and curcumin co-loaded liposphere gel: synergistic combination towards management of psoriasis","volume":"243","author":"Jain","year":"2016","journal-title":"J. Control. Release"}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641123000395?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641123000395?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:49:51Z","timestamp":1760546991000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641123000395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":34,"alternative-id":["S0939641123000395"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2023.02.007","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tacrolimus and paclitaxel co-loaded O\/O ointment without surfactant: Synergistic combinations for the treatment of psoriasis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2023.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}